Tetramethoxystilbene-Loaded Liposomes Restore Reactive-Oxygen-Species-Mediated Attenuation of Dilator Responses in Rat Aortic Vessels Ex vivo by Zaabalawi, Azziza et al.
Zaabalawi, Azziza and Astley, Cai and Renshall, Lewis and Beards,
Frances and Lightfoot, Adam P and Degens, Hans and Whitehead,
Debra and Alexander, Yvonne and Harris, Lynda K and Azzawi, May
(2019)Tetramethoxystilbene-Loaded Liposomes Restore Reactive-Oxygen-
Species-Mediated Attenuation of Dilator Responses in Rat Aortic Vessels Ex
vivo. Molecules, 24 (23). p. 4360.
Downloaded from: http://e-space.mmu.ac.uk/624533/
Version: Published Version
Publisher: MDPI AG
DOI: https://doi.org/10.3390/molecules24234360
Usage rights: Creative Commons: Attribution 4.0
Please cite the published version
https://e-space.mmu.ac.uk
  
Molecules 2019, 24, x; doi: FOR PEER REVIEW www.mdpi.com/journal/molecules 
Communication 1 
Tetramethoxystilbene-loaded liposomes restore 2 
reactive oxygen species-mediated attenuation of 3 
dilator responses in rat aortic vessels, ex vivo. 4 
Azziza Zaabalawi 1, Cai Astley 1, Lewis Renshall 2, 3, 4, , Frances Beards 2, 3, 4, Adam P. Lightfoot 5, 5 
Hans Degens 5, 6, Debra Whitehead 7, Yvonne Alexander 1, Lynda K Harris 2, 3, 4, May Azzawi 1*. 6 
1 Centre for Bioscience, Faculty of Science and Engineering, Manchester Metropolitan University, Chester 7 
Street, Manchester, M1 5GD. 8 
2 Division of Pharmacy and Optometry, University of Manchester, Oxford Road, Manchester, M13 9PL.  9 
3  Maternal and Fetal Health Research Centre, Faculty of Biology, Medicine and Health, University of 10 
Manchester, Oxford Road, Manchester, M13 9WL. 11 
4  Maternal and Fetal Health Research Centre, Manchester University NHS Foundation Trust, Manchester 12 
Academic Health Sciences Centre, St Mary’s Hospital, Manchester, M13 9WL. 13 
5  Centre for Musculoskeletal Science and Sports Medicine, Faculty of Science and Engineering, Manchester   14 
Metropolitan University, Chester Street, Manchester, M1 5GD.  15 
6 Lithuanian Sports University, Kaunas. 16 
7 Advances Materials and Surface Engineering Research Centre, Faculty of Science and Engineering, 17 
Manchester Metropolitan University, Chester Street, Manchester, M1 5GD.  18 
 19 
* Correspondence: M.Azzawi@mmu.ac.uk   20 
Received: date; Accepted: date; Published: date 21 
Abstract: The methylated analogue of the polyphenol Resveratrol (RV), 2, 3’, 4, 5’-22 
Tetramethoxystilbene (TMS) displays potent antioxidant properties and is an effective Cytochrome 23 
P450 (CYP) 1B1 inhibitor. The bioavailability of TMS is low. Therefore, the use of liposomes for the 24 
encapsulation of TMS is a promising delivery modality for enhanced uptake into tissues. We 25 
examined the effect of delivery of TMS in liposomes, on the restoration of vasodilator responses of 26 
isolated aortic vessels after acute tension elevation, ex vivo. Aortic vessels from young male Wistars 27 
were isolated and endothelial-dependent (acetylcholine, ACh) and independent (sodium 28 
nitroprusside, SNP) responses assessed. Acute tension elevation (1 hour) significantly reduced ACh 29 
dilator responses, which were restored following incubation with superoxide dismutase or 30 
apocynin (an NADPH oxidase inhibitor). Incubation with TMS-loaded liposomes (mean diameter 31 
157 ± 6 nm; PDI 0.097) significantly improved the attenuated dilator responses following tension 32 
elevation. Endothelial denudation or co-incubation with L-NNA (Nω-nitro-L-arginine; nitric oxide 33 
synthase inhibitor) resulted in loss of dilator function. Our findings suggest that TMS-loaded 34 
liposomes can restore attenuated endothelial-dependent dilator responses, induced by an oxidative 35 
environment, by reducing NADPH oxidase-derived ROS and potentiating the release of the 36 
vasodilator nitric oxide. TMS-loaded liposomes may be a promising therapeutic strategy to restore 37 
vasodilator function in vascular disease.  38 
Keywords: liposomes; 2, 3’, 4, 5’-Tetramethoxystilbene; endothelium; aorta; oxidative stress; 39 
reactive oxygen species; nitric oxide; vascular function. 40 
 41 
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1. Introduction 45 
 The vascular endothelial lining of blood vessels plays a pivotal role in the synthesis and release 46 
of highly regulated vasoactive substances, including the potent vasodilator nitric oxide (NO). An 47 
imbalance in the release of endothelial-derived vasodilator and vasoconstrictor mediators causes 48 
endothelial dysfunction (ED), that results in a dominant pro-vasoconstrictor state due to the 49 
generation of reactive oxygen species (ROS) and consequent reduction in NO bioavailability [1, 2]. 50 
ED is also associated with increased constriction, partly attributed to the decline in NO-mediated 51 
inhibition of potent vasoconstrictors, such 20-hydroxyeicosatetraenoic acid (20 HETE). The latter is 52 
a Cytochrome P450 (CYP) 1B1 eicosanoid, which has been shown to contribute to the development 53 
of hypertension [3]. Attractive supplements to current treatment strategies include plant-derived 54 
polyphenols such as Resveratrol (RV; 3, 5, 4′-trihydroxystilbene), due to its anti-oxidant properties 55 
and ability to regulate the endothelial nitric oxide synthase enzyme [eNOS] [4, 5]. Recent studies 56 
have been dedicated to developing derivatives of RV that have greater bioavailability and 57 
pharmacological activity than RV [6]. In particular, the methylated derivative of RV; 2, 3’, 4, 5’-58 
Tetramethoxystilbene (TMS), has been demonstrated to be 1000 times more potent in inhibiting 59 
CYP1B1 than RV in spontaneously hypertensive rats (SHR) [7]. Elevated CYP1B1 activity, 60 
endothelial dysfunction, ROS generation, NADPH oxidase activity and expression of NOX-1, ERK1 61 
/ 2 and p38 MAPK were diminished by TMS in the aorta, heart and kidney of the SHR model [7, 8]. 62 
Intravenous administration of TMS in rats shows moderate clearance (46.5 ± 7.6 mL / min /kg) [9] 63 
and better bioavailability (4.5%) [10], compared to RV, however, the absolute oral bioavailability of 64 
TMS remains low (6.31 ± 3.30%) [9].  65 
Liposomes are recognised as promising agents for drug delivery due to their biocompatibility 66 
and ability to cross physiological barriers [11, 12]. Liposomes have been clinically approved for 67 
medical applications, including anticancer treatment, owing to their higher therapeutic efficacy and 68 
low cytotoxicity. Major progress was made in their clinical application with the development of 69 
PEGylated liposomes. Displaying PEG (N-[amino (polyethylene glycol)] on the liposomal surface 70 
increases their circulation time by preventing opsonisation, uptake and elimination by phagocytes 71 
[12]. TMS encapsulated in PEGylated liposomes could thus serve as an attractive delivery system 72 
whilst preserving the stability of TMS and enhancing its bioavailability [13]. The aim of this study 73 
was to assess the potential of TMS-loaded liposomes to restore reduced vasodilator capacity of 74 
isolated aortic vessels exposed to acute tension elevation, ex vivo. 75 
2. Results 76 
2.1. Production and characterisation of TMS-loaded liposomes 77 
Phosphate buffered saline (PBS) containing liposomes (blank liposomes) had a mean diameter 78 
of 182 ± 3 nm, polydispersity index (PDI) of 0.081 and an average zeta potential of -13.17 ± 0.76 mV. 79 
TMS-loaded liposomes had a mean diameter of 157 ± 6 nm, PDI of 0.097 and an average zeta 80 
potential of -13.13 ± 0.67 mV, whereas liposomes containing the dye, 5(6)-carboxyfluorescein and 81 
TMS had a mean diameter of 150 ± 3 nm, PDI of 0.070 and an average zeta potential of -15.80 ± 1.31 82 
mV. All measurements were conducted at pH 7.2-7.4.    83 
Structural and functional characterisation of PEGylated liposomes were established using 84 
chemical techniques to confirm dye and drug entrapment within the liposomes. Fluorescence peaks 85 
were detected at 517 nm (corresponding to the dye) from TMS-dye encapsulated, but not blank or 86 
TMS-loaded liposomes (Figure 1A). Independent analysis of TMS solution identified two 87 
absorbance peaks at 302 and 326 nm, however, no peaks corresponding to TMS were 88 
distinguishable in either TMS- or TMS-dye encapsulated liposomes (Figure 1B). TMS has a similar 89 
infra-red profile to its well-characterised parent compound RV, with characteristic benzene valence 90 
v(C=C) vibrations identifiable at 1588 and 1570 cm-1. The strong, broad band characteristics of trans-91 
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RV are noticeably absent between 3550-3200 cm-1; however, several bands are identifiable at 2850, 92 
2952 and 3000 cm-1, corresponding to the valence vibration and stretching of O-CH3 bonds within 93 
synthetically conjugated methyl groups. Additional CH3 bending is observed at 1455 cm-1. Ether 94 
bonds (C-O-C) originating from phenolic groups are identifiable at 1026, 1152, 1195 and 1287 cm-1. 95 
The presence of TMS could not be identified in the liposomes due to the absence of corresponding 96 
peaks. The individual components of the liposomal structure, 1,2-distearoyl-sn-glycero-3-97 
phosphocholine and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 98 
glycol)-2000] ammonium salt were identifiable with peaks at 2950-2850 and 1730 cm-1, 99 
corresponding with the presence of alkane (C-H) and carbonyl ester groups (C=O). The broad peak 100 
observed at 3500 cm-1 are a result of OH grounds found within fatty acids (cholesterol). Additional 101 
vibrations corresponding with a C-C bond at 1248 cm-1 and a C-O bond from the phenolic group at 102 
1154 cm-1 were identified within the spectrum (Figure 1C, D).  103 
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Figure 1. Chemical characterisation of tetramethoxystilbene (TMS) and TMS - loaded liposomes. 108 
Fluorescence - spectroscopy displaying spectra between 500 – 700 nm (A). Ultraviolet - visible 109 
spectroscopy (UV - Vis) displaying absorbance spectra between 200 – 1000 nm (B). Fourier - 110 
transform infrared spectroscopy (FTIR) profile of TMS - powder (C) and TMS - loaded liposomes 111 
(D) displaying transmittance (%) ranging between 500 – 4000 nm.   112 
2.2. TMS-loaded liposomes maintain cell viability, in vitro 113 
Human coronary artery endothelial cell (HCAEC) viability did not differ significantly between 114 
control cells and cells incubated with TMS or TMS-loaded liposomes for 24 hours (Figure 2A). Drug 115 
encapsulation within liposomes has previously been shown to provide greater therapeutic efficacy 116 
with low cytotoxicity levels in human retinal endothelial cells [14]. In order to replicate elevated 117 
superoxide levels observed in the vasculature during oxidative stress, HCAECs were stimulated 118 
with hydrogen peroxide (H2O2) [15]. A reduction in fluorescence intensity, hence mitochondrial 119 
superoxide production, was observed following incubation in TMS-loaded liposomes (Figure 2B). 120 
C 
D 
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Figure 2. In vitro studies. Alamar blue cell viability assay performed in a 96 - well plate following 123 
administration of cumulative doses of tetramethoxystilbene (TMS) and TMS - loaded liposomes for 124 
24 hours (A). Mitochondrial superoxide generation in human coronary artery endothelial cells 125 
measured using MitoSOX Red reagent. Assays performed in a 96 - well plate with cells treated with 126 
TMS - loaded liposomes for 24 hours, followed by hydrogen peroxide (H2O2) 500 μM exposure. 127 
Untreated cells received media alone (B). Data are presented as mean ± standard error of mean, n = 128 
3. 129 
2.3. TMS-loaded liposomes restore endothelium-dependent dilation via Nitric oxide   130 
All vessels constricted to high potassium (KPSS, 60 mM) and phenylephrine (Phe) (10-5 M) 131 
solution. Acute tension elevation significantly attenuated endothelium-dependent dilation to 132 
acetylcholine (ACh), which was restored following co-incubation with superoxide dismutase 133 
(Figure 3A) or the NADPH oxidase inhibitor, apocynin (Figure 3B). This reduction in dilation 134 
following tension elevation was significantly potentiated after incubation in TMS or TMS-loaded 135 
liposomes. Incubation with blank liposomes did not alter ACh dilator responses (Figure 3C). There 136 
B 
A 
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was a significant reduction in dilator responses following inhibition of nitric oxide synthesis by L-137 
NNA (Figure 3D). Vessels did not dilate to ACh following acute tension elevation and incubation 138 
with TMS or TMS-loaded liposomes after endothelial denudation (Figure 3E). TMS and TMS-139 
loaded liposomes had no effect on endothelial-independent (SNP) dilation (data not shown).  140 
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Figure 3. Vascular responses. Endothelium - dependent acetylcholine (ACh) responses in control 148 
vessels (control - 2g tension), following acute tension elevation (4g), acute tension elevation + 149 
superoxide dismutase (SOD) (A) and tension elevation + apocynin (B) in phenylephrine pre-150 
constricted aortic vessels, ex vivo. The influence of tetramethoxystilbene (TMS), TMS - loaded 151 
liposomes and blank liposomes (C), the inhibitor Nω – nitro - L-arginine (LNNA) (D) and 152 
endothelial denudation (E) on endothelium - dependent ACh responses following acute tension 153 
elevation in phenylephrine pre-constricted aortic vessels, ex vivo. ** = P < 0.01, *** = P < 0.001. Error 154 
bars = standard error.  155 
3. Discussion 156 
We demonstrate that TMS, loaded within liposomes, can restore the reduced aortic vasodilator 157 
response, induced by a high oxidative environment, by potentiating the NO pathway. We produced 158 
TMS-loaded liposomes for direct uptake into the vasculature. These were characterised and dye 159 
loading confirmed using a range of chemical techniques. Due to the limited content that can be 160 
encapsulated within liposomes, a substantial absorbance peak would not be expected and may, 161 
therefore, be obscured by more prominent absorption peaks, as seen at 207 nm. This intense 162 
absorption towards the lower detection range has previously been observed in liposome samples 163 
and has been attributed to the presence of cholesterol. Cholesterol and other well-known oxysterols 164 
have been shown to absorb light at approximately 195 nm (vacuum-UV region). However, light 165 
scattering results in the λ max shifting towards a longer wavelength, producing an effect commonly 166 
referred to as false-energy. This results in a spectral ‘redshift’, with spectra now appearing in the 167 
207 nm region [16]. Using FTIR we identified several peaks which corresponded with the parent 168 
compound RV, confirming its derived nature. FTIR also confirmed the presence of constituent 169 
compounds used to synthesise the liposomes; however, the spectrographic profile for TMS was not 170 
distinguishable. Similar observations have been reported previously by several research groups, 171 
where nanoparticles are capable of obscuring the absorption peaks of encapsulated drugs, showing 172 
only the predominant parent compounds [17]. In the context of polyphenolic compounds, the 173 
presence of OH groups are commonplace and would be expected at around 3500 cm-1. Despite 174 
being synthesised from a polyphenolic parent compound, it is crucial to note that in TMS, OH 175 
groups have been substituted for synthetically conjugated methyl groups, and as a result would not 176 
expect valance vibration bands at 3500 cm-1. This, in addition to the presence of the same broad 177 
peak on blank liposomes are suggestive that the vibration observed are solely from the lipid 178 
E 
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components. The distribution and intensity of absorption (% transmission) bands (blank vs. TMS-179 
loaded liposome) are a direct reflection of the range and quantity of chemical bonds present within 180 
a given sample. In some instances, this may reflect an increase or decrease in band intensity, as a 181 
result of sample modification and altered chemical composition. In this case, however, differences 182 
in intensity observed between samples can be attributed to different dilution ratios of stock 183 
samples.  184 
Using isolated HCAECs in culture, we demonstrate that TMS-loaded liposomes can maintain 185 
cell viability. When the cells were exposed to H2O2, mitochondrial superoxide generation was 186 
reduced following 24 hour incubation with TMS-loaded liposomes. The lack of significance in 187 
reduction suggests that TMS-loaded liposomes may quench additional sources of ROS, including 188 
cytosolic superoxide, due to NADPH oxidase stimulation and NOS uncoupling [15]. Furthermore, 189 
TMS-loaded liposomes may also influence the upregulation of antioxidant enzymes and eNOS 190 
expression in a similar way to resveratrol [18, 19]. To demonstrate the vasodilator potential of the 191 
TMS-loaded liposomes, we used aortic vessels, exposed to elevated tension, to generate an 192 
oxidative environment. The upregulation of ROS sources particularly NADPH oxidase, decreases 193 
SOD activity and causes eNOS uncoupling [2]. Vessel incubation with the NADPH oxidase 194 
inhibitor apocynin significantly potentiated dilator responses following tension elevation. This is 195 
consistent with previous findings that NADPH oxidase is the major ROS generator in the 196 
vasculature [20]. Apocynin blocks the translocation of p47phox to the membrane, hence preventing 197 
the release of NADPH oxidase-derived superoxide [21].   198 
Vessel incubation with TMS / TMS-loaded liposomes restored endothelium-dependent dilator 199 
responses following tension elevation even beyond the maximal dilation observed in control 200 
vessels. TMS has been documented to reduce the increase in NADPH oxidase-derived ROS in 201 
aortic, mesenteric and renal arteries of spontaneously hypertensive rats (SHR) primarily via 202 
inhibition of CYP1B1 activity. CYP1B1 has been reported to contribute to ED in SHR, with TMS 203 
reversing this effect as indicated by improvement in vasodilation in response to ACh [7]. It appears 204 
that ED in SHR and DOCA hypertensive models occurs largely as a result of elevated ROS 205 
generation, resulting from Arachidonic Acid (AA) metabolites such as 20-HETE that is produced by 206 
CYP1B1. This subsequently elevates NADPH oxidase activity and ROS levels resulting in the 207 
activation of signalling molecules including ERK1 / 2, p38 MAPK and c-Src [22]. This was prevented 208 
by TMS treatment [8].The potentiation in dilator responses demonstrated by TMS can be 209 
attributable to increased eNOS phosphorylation, reduced NADPH oxidase-derived ROS and eNOS 210 
uncoupling via CYP1B1 inhibition, direct quenching of ROS and the activation of SIRT1 and / or 211 
AMPK pathway leading to elevated NO bioavailability. Inhibition of NO synthesis using L-NNA 212 
significantly attenuated the restored vasodilation by TMS / TMS-liposomes, suggesting its 213 
mechanism of action is mainly mediated via the NO pathway, which plays a major role in the 214 
maintenance of basal vasomotor tone in conduit vessels under normal but also under hypertensive 215 
conditions [23]. The dilator potential of TMS / TMS-liposomes was lost in denuded vessels, further 216 
suggesting that the potentiated dilation is mainly mediated via endothelial dependent mechanisms. 217 
The potentiation of dilator capacity by TMS-loaded liposomes to a higher extent than TMS solution, 218 
may be due to increased cellular uptake of liposomes, enhanced solubility and sustained release of 219 
encapsulated TMS [12] as compared to the rapid depletion / washout of TMS solution in the 220 
experimental setup. Therefore, we propose that the enhanced dilator effects of TMS-loaded 221 
liposomes is retained due to slow continued release of encapsulated TMS that has already been 222 
taken up by the cells.       223 
4. Conclusion 224 
In the present study, we exposed isolated aortic vessels to elevated tension, ex vivo, to generate 225 
an oxidative environment, in order to examine the effects of TMS-loaded liposomes in restoring 226 
dilator capacity. We demonstrate that TMS-loaded liposomes can restore the attenuated 227 
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endothelial-dependent dilator responses, by reducing NADPH oxidase-derived ROS and 228 
potentiating NO mediated dilation. TMS-loaded liposomes may thus be a promising therapeutic 229 
strategy to improve vasodilator function in vascular disease. 230 
5. Materials and Methods  231 
5.1. Chemicals, Reagents and Materials 232 
2, 3’, 4, 5’-Tetramethoxystilbene (TMS) and all reagents were purchased from Sigma-Aldrich, 233 
UK. Physiological salt solution (PSS) had the following composition [mM]: 119 NaCl, 4.7 KCl, 1.2 234 
MgSO47H2O, de-ionised (dH2O), 25 NAHCO3, 1.17 KHPO4, 0.03 K2EDTA, 5.5 glucose, 1.6 CaCl2H2O; 235 
pH 7.4.  236 
5.2. Liposome Synthesis and Characterisation 237 
Liposomes were synthesised using the thin lipid film process as previously described [24, 25]. 238 
Briefly, the constituent lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; 32.5 mM, Avanti 239 
Polar Lipids), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-240 
2000] ammonium salt [DSPE-PEG(200); 1.875 mM, Avanti Polar Lipids] and cholesterol (15 mM, 241 
Sigma Aldrich) were dissolved in 5 ml of chloroform in a round-bottom flask. Subsequent rotary 242 
evaporation (40°C, 270 mbar) removed excess chloroform and the lipid film was placed in a 243 
vacuum oven overnight (25°C, 0 mbar). The thin film was rehydrated with 1 ml of PBS, vortexed for 244 
10 minutes, heated to 55°C and vortexed for 5 minutes at 1 hour intervals for a minimum of 4 hours. 245 
The suspension containing large multilamellar vesicles was then extruded 11 times using a 1 ml 246 
Mini-Extruder (Avanti Polar Lipids) through a 200 nm polycarbonate membrane to produce 247 
unilamellar liposomes ~200 nm in diameter. To remove impurities, dialysis against PBS (8 x 500 ml; 248 
24 hours) in a Slide-A-Lyzer cassette with a molecular weight cutoff of 3.5 kD (Thermo Fisher 249 
Scientific) was performed. Liposomes were then stored at 4°C until use. The size distribution and 250 
polydispersity index of liposomes were measured by dynamic light scattering (DLS; 25oC; 251 
scattering angle of 173o Zetasizer Nano ZS, Model ZEN3600, Malvern Instruments). For TMS-252 
loaded liposomes, the lipid film was rehydrated with 1 ml TMS (2 mM in PBS) heated to 55oC and 253 
extruded / dialysed as above, to give a final encapsulated concentration of approximately 1 mM 254 
TMS. For dual-loaded TMS / 5(6)-carboxyfluorescein liposomes a 1ml solution of TMS (2 mM) 255 
containing 5(6)-carboxyfluorescein (5.3 mM) was used to rehydrate the lipid film, to give a final 256 
concentration of 1 mM and 2.65 mM, respectively. UV–Vis spectrophotometer (Jenway 7305, Cole-257 
Palmer) and fluorescence spectrometer (F-7000, Hitachi) was used to determine absorption and 258 
fluorescence spectra, respectively. The structure of liposomes was assessed using FTIR (Nicolet 380 259 
FT-IR Spectrometer, Thermo Scientific). 260 
5.3. Cell Culture Studies 261 
HCAECs were purchased from PromoCell (Heidelberg, Germany). Cells were grown in 262 
Endothelial Cell Growth Medium (MV2) supplemented with growth medium MV2 supplement 263 
pack, 100 μl / mL penicillin and 100 μl / mL streptomycin. Cells were maintained at 37°C with 4% 264 
CO2 in a humidified incubator and subcultured 1:3 after reaching 80% confluency. The viability of 265 
HCAECs was determined using the fluorometric Alamar Blue Cell Viability assay. HCAECs were 266 
seeded in 96-well plates and exposed to increasing doses of TMS solution and TMS liposomes (1 267 
nM- 1 µM) for 24 hours. Fluorescence was measured at ex. 570 / em. 590 nm using a BioTek Synergy 268 
HT microplate reader. The generation of intracellular superoxide was quantified using MitoSOX 269 
Red Mitochondrial Superoxide Indicator (Thermo, UK). Briefly, HCAECs were cultured on 96-well 270 
plates at a density of 1 x 104 cells / well for 24 hours. Cells were then incubated with TMS-loaded 271 
liposomes (10 and 1 nM) for 24 hours, washed, then incubated with fresh medium in the presence 272 
of 500 μM H2O2 for 30 minutes. Cells were incubated in the dark at 37°C with MitoSOX for 10 273 
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minutes. Fluorescence was measured at ex. 510 / em. 580 nm (BioTek Synergy HT microplate 274 
reader).  275 
5.4. Vascular Function Studies  276 
Aortic vessels were excised from male Wistar rats (150-250 g) euthanized by stunning and 277 
cervical dislocation, following Institutional guidelines and in accordance with the ‘Animals 278 
Scientific procedures act 1986’. The heart was isolated and kept in oxygenated PSS (95% O2: 5% CO2; 279 
4˚C) in a dissection dish. The aortic vessel was gently pinned down at both ends and the underlying 280 
adipose tissue was removed using dissection scissors and forceps, under a binocular dissection 281 
microscope with a fibre optic light source (Olympus SZ61). The vessel was then cut into 3 mm rings 282 
and mounted between two fine steel wires in a calibrated organ-bath system, immersed in 283 
oxygenated PSS at 35˚C, then placed under 2g tension using Harvard isometric strain transducer 284 
and tension recorded using Labchart 8 (Power lab, AD Instruments, UK), as previously described 285 
[26]. The viability of blood vessels was examined by ascertaining initial responses to high 286 
potassium solution (KPSS, 60 mM). Vessels that recorded constrictor responses of <1.0 g tension 287 
were not considered viable and were excluded from the study. The influence of TMS / TMS-loaded 288 
liposomes on blood vessel function was determined in response to vasodilator agonists including; 289 
acetylcholine (ACh) (10-9 M - 10-4 M), sodium nitroprusside (SNP) (100 nM) and the vasoconstrictor, 290 
Phenylephrine (Phe) (10-5 M).   291 
Endothelial-dependent (ACh) and independent (SNP) responses were examined following 292 
acute tension elevation (4g, 1 hour) in the presence / absence of TMS / TMS-loaded liposomes. In 293 
order to establish the minimal dose of TMS required to achieve maximal dilation, cumulative doses 294 
of TMS (1 pM-10 mM) were added to pre-constricted vessels with Phe. In order to assess the dilator 295 
effect of superoxide dismutase (SOD) and TMS / TMS-loaded liposomes, aortic rings were initially 296 
placed under elevated tension (4 g, 1 hour), followed by a 30 minute incubation with SOD (300 U / 297 
mL) or TMS / TMS-loaded liposomes (1 nM). Constrictor and dilator responses were investigated 298 
and recorded. To evaluate the dilator component involved in the action of TMS / TMS-loaded 299 
liposomes, inhibition studies were performed. LNNA (NO synthesis inhibitor; 100 μM) was used to 300 
evaluate the influence of NO following acute tension elevation with and without incubation with 301 
TMS / TMS-loaded liposomes. To assess the contribution of NADPH oxidase on the dilator function 302 
of TMS / TMS-loaded liposomes, apocynin (0.3 mM, 30 minutes) was used to block NADPH 303 
oxidase activity. Endothelial denudation was used to assess the endothelial dependent dilator 304 
component of TMS / TMS-loaded liposomes. To investigate any effects of the liposomes alone on 305 
vasodilation, aortic vessels were incubated with blank liposomes (drug-free) (1 nM) for 30 minutes 306 
after tension elevation. Constrictor and dilator responses to Phe and ACh was measured, 307 
respectively. 308 
5.5. Statistical Analysis  309 
All values are presented as mean ± standard error. Data were tested for normal distribution 310 
using Shapiro-Wilk test. Results were analysed using a two-way ANOVA followed by Tukey’s 311 
multiple comparisons post-test (IBM SPSS Statistics 25). Statistical significance is P < 0.05. * = P < 312 
0.05, ** = P < 0.01, *** = P < 0.001. P > 0.05 was considered non-significant.                         313 
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